COMMUNIQUÉS West-GlobeNewswire

Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO
23/03/2019
New Orleans, US , 23 March 2019 - Oral semaglutide 7 mg and 14 mg demonstrated superior HbA 1c and body weight reductions compared to Januvia ® (sitagliptin 100 mg). Non-inferiority for oral semaglutide 3 mg for HbA 1c [...]
Radius Health Presents Analysis from Phase 3 ACTIVE Trial and Data from Preclinical Studies for TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting
23/03/2019
-Post-hoc analysis suggests abaloparatide may be useful in the treatment of women with postmenopausal osteoporosis and concurrent osteoarthritis, at high risk for fracture- -Preclinical studies provide explanations for [...]
InspireMD Provides Amended Disclosure
22/03/2019
TEL AVIV, Israel, March 22, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery [...]
Healthcare Special Opportunities Fund Announces March 2019 Quarterly Distribution
22/03/2019
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, March 22, 2019 (GLOBE NEWSWIRE) -- ( TSX: MDS.UN ) – LDIC Inc. (the “ Manager ”), the manager of Healthcare Special [...]
U.S. Healthcare Leader Joseph R. Swedish Appointed Mesoblast Chairman
22/03/2019
NEW YORK and MELBOURNE, Australia, March 22, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today announced it has appointed Joseph R. Swedish as non-executive Chairman. Mr Swedish will succeed [...]
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22/03/2019
WALTHAM Mass., and CRESTWOOD, Ky., March 22, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]
Neuralstem Reports Year End 2018 Fiscal Results
22/03/2019
GERMANTOWN, Md., March 22, 2019 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule [...]
Y-mAbs Announces 2018 Financial Results and Corporate Development Highlights
22/03/2019
NEW YORK, March 22, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel [...]
IntelGenx Reports Fourth Quarter and Full-Year 2018 Financial Results
22/03/2019
SAINT LAURENT, Quebec, March 22, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results for the fourth quarter and twelve-month [...]
Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
22/03/2019
MENLO PARK, Calif., March 22, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies [...]
BioSyent Announces Notice of Deficiency for Cardiovascular Products
22/03/2019
TORONTO, March 22, 2019 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that it has been informed by Health Canada that the Company will receive a Notice of Deficiency (“NOD”) [...]
Junior Welterweight Blair "The Flair" Cobbs Sports Diamond CBD Logo in Championship-Winning Fight
22/03/2019
CBD company extends its presence both inside and out of the ring FT. LAUDERDALE, Fla., March 22, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Diamond CBD Inc., a wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC [...]
Tecan to vertically integrate supplier of key parts
22/03/2019
Männedorf, Switzerland, March 22, 2019 – The Tecan Group (SIX Swiss Exchange: TECN) announced today that it has signed agreements to acquire a long-term supplier to vertically integrate the manufacturing of critical [...]
Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
22/03/2019
Management to Host Conference Call and Webcast Today at 4:30 p.m. ET MALVERN, Pa., March 22, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on [...]
Sanofi: FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin)
22/03/2019
FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin) PARIS and THE WOODLANDS, TX - March 22, 2019 - The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New [...]
Sanofi : La FDA publie une lettre de réponse complète au sujet de Zynquista(TM) (sotagliflozine)
22/03/2019
La FDA publie une lettre de réponse complète au sujet de Zynquista(TM) (sotagliflozine) Paris et The Woodlands (Texas) - Le 22 mars 2019 - La Food and Drug Administration (FDA) des États-Unis a publié une lettre de [...]
Lexicon Pharmaceuticals to Host Conference Call and Webcast Today, March 22, 2019 to Provide a Regulatory Update on Sotagliflozin in Type 1 Diabetes
22/03/2019
THE WOODLANDS, Texas, March 22, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that management will conduct a conference call and live webcast today, Friday, March 22, 2019, at 2: [...]
FDA Issues Complete Response Letter for Zynquista™ (sotagliflozin)
22/03/2019
PARIS and THE WOODLANDS, Texas, March 22, 2019 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for investigational Zynquista™ ( [...]
IBA SA: transparency notification
22/03/2019
IBA – TRANSPARENCY NOTIFICATION Louvain-la-Neuve, Belgium, March 22, 2019, 17.35 - IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it [...]

Pages